Skip to content
FY'25FY'24FY'23FY'22
Profitability
Operating margin-11.2%+266pp-277.3%+1,030pp-1,307%-466pp-841.3%
Net margin-3.7%+240pp-243.4%+949pp-1,192.3%-378pp-814.8%
EBITDA margin-10.2%+261pp-271.4%+1,008pp-1,278.9%-450pp-828.9%
Returns
Return on equity-2.4%+43.4pp-45.8%+15.0pp-60.8%-10.6pp-50.2%-16.1pp
Return on assets-2%+33.6pp-35.6%+7.6pp-43.2%-2.4pp-40.8%-8.9pp
Return on invested capital-10.9%-133.6%
Efficiency
Asset turnover0.5×+0.4×0.1×+0.1×0.0×0.1×
Liquidity
Current ratio5.3×-0.5×5.8×-1.2×-0.8×7.8×-5.6×
Quick ratio5.3×-0.5×5.8×-1.2×-0.8×7.8×-5.6×
Cash ratio1.5×-1.7×3.2×-3.0×6.2×+2.6×3.6×-4.8×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Interest coverage-1.5×+6.5×-8×+3.6×-11.6×+21.8×-33.4×+684×
Per Share
Book value per share$5.95+40.4%$4.24+16.9%$3.63-23.7%$4.75-19.8%
Valuation
Market capitalization$1.81B+210%$584.23M+147%$236.48M-35.0%$363.98M-58.8%
Enterprise value$1.73B+276%$461.02M+789%$51.88M-79.7%$255.5M-65.7%
Price / sales9.8×-6.2×16×-10.9×26.9×-2.4×29.3×
Price / book5.1×+2.6×2.6×+1.1×1.5×-0.5×-2.1×
EV / sales9.4×-3.2×12.6×+6.7×5.9×-14.7×20.6×
Earnings yield-0.4%+14.9pp-15.2%+29.0pp-44.3%-16.5pp-27.8%-18.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Stoke Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Stoke Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.